ResearchAndMarkets.com has added a report forecasting the Von Willebrand disease market across the seven major markets (7MM) from 2022 to 2036. The United States is expected to remain the largest market, while the EU4, the United Kingdom and Japan offer significant commercial opportunities as diagnosis and treatment access improve. Diagnosed prevalence is projected to rise through 2036, although delayed diagnosis, testing variability, subtype classification difficulties, limited specialist access and breakthrough bleeding remain important unmet needs. Established therapies include WILATE from Octapharma and VONVENDI/VEYVONDI (vonicog alfa) from Takeda Pharmaceuticals. The report also assesses investigational candidates VGA039, HMB-002 and ALN-6400, alongside market size, epidemiology, patient uptake, pricing, regulatory milestones, market access and competitive positioning.